



Zdravstveni sistem v Nemciji

dr. Marko Obradovic

Senior HEOR Manager

Grünenthal GmbH

Aachen, DE

- 16 dežel
- Berlin (gl. mesto)
- Parlamentarna demokracija (Bundestag)
- 82,5 mio prebivalcev







Nemski zdr. sistem ima ugled enega najboljših na svetu...

- DOSTOPNOST:
 - Gosta mreza bolnisnic
 - Dostopnost do zdravnikov tudi v najbolj odrocnih predelih
 - Skoraj vsi imajo dostop do zdr. storitev, ne glede na dohodek oz. druzbeni status

- Cakalne dobe so redke

- Najnovejsa opremljenost

- Obvezno zavarovanje krije zelo velik del stroskov

Euro Health Consumer Index 2008

For more info please visit: www.healthpowerhouse.com

Euro Health Consumer Index at a glance:

Winner: Netherlands
 Runner-up: Denmark
 Third place: Austria

Subcategories:

Patient rights and information: Denmark

e-Health: Denmark

Waiting time for treatment: Germany, Luxembourg, Switzerland

Outcomes: Sweden

Range and reach of services provided: Netherlands

Pharmaceuticals: Austria

- = Good
- = Intermediary
- = Poor
- n.a. = Data not available

| SUBDISCIPLINE | INDICATOR | Austria | Belgium | Bulgaria | Czechia | Cyprus | Czech Republic | Denmark | Estonia | Finland | France | Germany | Greece | Hungary | Ireland | Italy | Lithuania | Luxembourg | Malta | Netherlands | Poland | Portugal | Romania | Slovakia | Slovenia | Spain | Sweden | Switzerland | United Kingdom | | | |
|--------------------------------------|---|---------|---------|----------|---------|--------|----------------|---------|---------|---------|--------|---------|--------|---------|---------|-------|-----------|------------|-------|-------------|--------|----------|---------|----------|----------|-------|--------|-------------|----------------|-----|-----|-----|
| Patient rights and information | Healthcare law based on Patients' Rights | ● | ● | ○ | ● | ○ | ○ | ● | ● | ● | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| | Patient organizations involved in decision making | ○ | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| | No-bail retractive insurance | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| | Right to second opinion | ● | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| | Access to own medical record | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| | Register of legit doctors | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| | Web or 24/7 telephone HC info | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| | Cross-border care information | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | n.a. | | | | |
| | Subdiscipline weighted score | 100 | 105 | 88 | 94 | 88 | 81 | 144 | 125 | 131 | 113 | 81 | 100 | 100 | 119 | 88 | 100 | 56 | 131 | 105 | 94 | 125 | 106 | 94 | 63 | 81 | 94 | 119 | 75 | 100 | 100 | 94 |
| | Provider catalogue with quality ranking | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | |
| e-Health | IP4 penetration | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| | e-transfer of medical data | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | n.a. | | | | |
| | e-prescriptions | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | n.a. | | | | |
| | Subdiscipline weighted score | 50 | 42 | 50 | 33 | 50 | 42 | 100 | 50 | 58 | 50 | 50 | 50 | 56 | 42 | 42 | 33 | 33 | 42 | 33 | 92 | 75 | 33 | 42 | 33 | 42 | 50 | 50 | 75 | 50 | 92 | |
| | Provider catalogue with quality ranking | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | |
| Waiting time for treatment | Family doctor same day access | ● | ● | ● | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| | Direct access to specialist | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| | Major non-acute operations <90 days | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| | Cancer therapy < 21 days | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| | MRI scan < 7 days | ● | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| Subdiscipline weighted score | 173 | 173 | 133 | 93 | 120 | 147 | 120 | 147 | 80 | 133 | 93 | 187 | 133 | 160 | 107 | 120 | 67 | 120 | 187 | 107 | 133 | 107 | 107 | 80 | 160 | 133 | 80 | 93 | 80 | 187 | 93 | |
| Outcomes | Heart infarct case fatality | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| | Infant deaths | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| | Cancer 5 year survival | ● | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| | Amicable deaths - years of life lost | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| | MRSA infections | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| | Rate of decline of suicide | ○ | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | n.a. | | | | |
| | % of patients with high HbA1c levels (> 7) | ○ | ○ | n.a. | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | n.a. | ○ | n.a. | n.a. | n.a. | ○ | ○ | n.a. | | | | |
| | Subdiscipline weighted score | 202 | 131 | 107 | 119 | 143 | 179 | 214 | 143 | 214 | 190 | 117 | 100 | 110 | 131 | 190 | 100 | 143 | 119 | 100 | 110 | 214 | 202 | 131 | 131 | 71 | 95 | 187 | 179 | 238 | 187 | 155 |
| Range and reach of services provided | Cataract operations per 100 000 | ○ | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| | Infant 4-disease vaccination | ○ | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| | Kidney transplants per million pop. | ● | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| | Dental care affordability | ● | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| | Rate of mammography | ○ | ○ | n.a. | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | n.a. | n.a. | ○ | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | | | | |
| | Minimal payments to doctors | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| | Subdiscipline weighted score | 106 | 133 | 58 | 75 | 75 | 92 | 117 | 92 | 133 | 106 | 100 | 100 | 92 | 92 | 100 | 100 | 67 | 133 | 92 | 150 | 117 | 63 | 92 | 67 | 92 | 92 | 117 | 125 | 83 | 117 | |
| Pharmaceuticals | Rx subsidy | ● | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| | Layman-adapted pharmacopeia? | ● | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| | New cancer drugs deployment speed | ● | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| | Access to new drugs (time to subsidy) | ● | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | | | | |
| | Subdiscipline weighted score | 150 | 75 | 50 | 50 | 80 | 100 | 125 | 113 | 80 | 100 | 80 | 113 | 80 | 80 | 125 | 80 | 50 | 50 | 100 | 80 | 125 | 100 | 63 | 100 | 75 | 100 | 75 | 125 | 125 | 100 | |
| TOTAL SCORE | | 784 | 661 | 486 | 464 | 563 | 640 | 820 | 660 | 705 | 605 | 486 | 740 | 500 | 647 | 643 | 610 | 440 | 520 | 758 | 532 | 839 | 707 | 511 | 507 | 488 | 556 | 582 | 630 | 743 | 712 | 650 |
| RANK | | 3 | 12 | 28 | 29 | 21 | 16 | 2 | 11 | 9 | 10 | 3 | 6 | 19 | 14 | 15 | 16 | 31 | 24 | 4 | 23 | 1 | 8 | 25 | 26 | 27 | 22 | 20 | 18 | 5 | 7 | 13 |



Euro Health Consumer Index 2008

SUBDISCIPLINE

Patient rights and information

For more info please visit www.eurohealthconsumerindex.com

Euro Health Consumer Index at a glance:
Winner: Netherlands
Runner-up: Denmark
Third place: Austria

Subcategories:

Patient rights and information: Denmark

e-Health: Denmark

Waiting time for treatment: Germany, Luxembourg, Switzerland

Outcomes: Sweden

Range and reach of services provided: Netherlands

Pharmaceuticals: Austria

- = Good
- = Intermediary
- = Poor
- n.a. = Data not available

| | Austria | Belgium | Denmark | France | Germany | Greece | Italy | Netherlands | Norway | Poland | Portugal | Romania | Sweden | Switzerland | United Kingdom |
|---|---------|---------|---------|--------|---------|--------|-------|-------------|--------|--------|----------|---------|--------|-------------|----------------|
| Patient rights and information | | | | | | | | | | | | | | | |
| Patients' Rights | ● | ● | ○ | ● | ● | ○ | ● | ● | ○ | ● | ● | ● | ● | ● | ● |
| Informed in decision making | ○ | ● | ○ | ● | ● | ○ | ● | ● | ○ | ● | ● | ○ | ● | ● | ● |
| Choice | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Right of refusal | ● | ● | ○ | ● | ○ | ○ | ● | ● | ○ | ● | ○ | ○ | ● | ○ | ○ |
| Access to information | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Information | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Subdiscipline weighted score | 100 | 106 | 88 | 94 | 88 | 81 | 144 | 125 | 131 | 113 | 88 | 100 | 100 | 100 | 100 |
| Subdiscipline weighted score with quality ranking | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| e-Health | | | | | | | | | | | | | | | |
| e-transfer of medical data | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| e-prescriptions | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Subdiscipline weighted score | 50 | 42 | 50 | 33 | 50 | 42 | 100 | 50 | 58 | 50 | 50 | 50 | 33 | 58 | 42 |
| Waiting time for treatment | | | | | | | | | | | | | | | |
| Family doctor same day access | ● | ● | ● | ● | ○ | ● | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Direct access to specialist | ● | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Major non-acute operations < 30 days | ○ | ● | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Cancer therapy < 21 days | ○ | ● | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| MRI scan < 7 days | ● | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Subdiscipline weighted score | 173 | 173 | 133 | 93 | 120 | 147 | 120 | 147 | 80 | 133 | 93 | 187 | 133 | 160 | 107 |
| Outcomes | | | | | | | | | | | | | | | |
| Heart Infarct case fatality | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Infant deaths | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Cancer 5-year survival | ● | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Avoidable deaths – years of Life Lost | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| MRSA Infections | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Rate of decline of suicide | ○ | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| % of patients with high HbA1c levels (> 7) | ○ | ○ | n.a. | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Subdiscipline weighted score | 202 | 131 | 107 | 119 | 143 | 179 | 214 | 143 | 214 | 190 | 107 | 190 | 179 | 131 | 190 |
| Range and reach of services provided | | | | | | | | | | | | | | | |
| Cataract operations per 100 000 | ○ | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Infant 4-disease vaccination | ○ | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Kidney transplants per million pop. | ● | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Dental care affordability | ● | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Rate of mammography | ○ | ○ | n.a. | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Informal payments to doctors | ○ | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Subdiscipline weighted score | 108 | 133 | 58 | 75 | 75 | 92 | 117 | 92 | 133 | 108 | 75 | 100 | 67 | 92 | 92 |
| Pharmaceuticals | | | | | | | | | | | | | | | |
| Rx subsidy | ● | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Layman-adapted pharmacopels? | ● | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| New cancer drugs deployment speed | ● | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Access to new drugs (time to subsidy) | ● | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |

Euro Health Consumer Index 2008

For more info please visit: www.healthpowerhouse.com

Euro Health Consumer Index at a glance:

Winner: Netherlands
Runner-up: Denmark
Third place: Austria

Subcategories:

Patient rights and information
 Denmark

e-Health:
 Denmark

Waiting time for treatment:
 Germany
 Switzerland

Outcomes:
 Sweden

Range and reach of services provided:
 Netherlands

Pharmaceuticals:
 Austria

| SUBDISCIPLINE | INDICATOR | Austria | Belgium | Bulgaria | Croatia | Cyprus | Czech Republic | Denmark | Estonia | Finland | France | FR Macedonia | Germany | Greece | Hungary | Ireland | Italy | Lithuania | Luxembourg | Malta | Netherlands | Norway | Poland | Portugal | Romania | Slovenia | Spain | Sweden | Switzerland |
|---------------------------------------|---|--------------------------------|---------|----------|---------|--------|----------------|---------|---------|---------|--------|--------------|---------|--------|---------|---------|-------|-----------|------------|-------|-------------|--------|--------|----------|---------|----------|-------|--------|-------------|
| Patient rights and information | Healthcare law based on Patients' Rights | ● | ● | ○ | ● | ● | ○ | ● | ● | ● | ● | ● | ○ | ● | ● | ○ | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| | Patient organisations involved in decision making | ○ | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| | No-fault malpractice insurance | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| | Right to second opinion | ● | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| | Access to own medical record | ● | ○ | ● | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| | EMR policies | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| | e-transfer of medical data | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ |
| | e-prescriptions | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| | Subdiscipline weighted score | | 106 | 88 | 94 | 88 | 81 | 144 | 125 | 131 | 113 | 88 | 109 | 100 | 100 | 119 | 88 | 100 | 56 | 131 | 106 | 94 | 125 | 106 | 94 | 63 | 81 | 9 | |
| | Waiting time for treatment | Family doctor same day access | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Direct access to specialist | | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |
| Major non-acute operations <90 days | | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |
| Cancer therapy < 21 days | | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |
| MRI scan < 7days | | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |
| Subdiscipline weighted score | | 120 | 147 | 120 | 147 | 80 | 133 | 93 | 187 | 133 | 160 | 107 | 120 | 67 | 120 | 187 | 107 | 133 | 107 | 107 | 80 | 160 | 11 | 1 | 1 | 1 | 1 | | |
| Heart Infarct case fatality | | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |
| Infant deaths | | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |
| Subdiscipline weighted score | | 202 | 131 | 107 | 119 | 143 | 179 | 214 | 143 | 214 | 190 | 107 | 190 | 179 | 131 | 190 | 190 | 143 | 119 | 190 | 119 | 214 | 202 | 131 | 131 | 71 | 9 | | |
| Range and reach of services provided | | Cabrect operations per 100 000 | ○ | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| | Infant 4-disease vaccination | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |
| | Kidney transplants per million pop. | ● | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |
| | Dental care affordability | ● | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | |
| | Rate of mammography | ○ | ○ | n.a. | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | n.a. | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |
| | Informal payments to doctors | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |
| | Subdiscipline weighted score | | 108 | 133 | 58 | 75 | 75 | 92 | 117 | 92 | 133 | 108 | 75 | 100 | 67 | 92 | 92 | 100 | 100 | 67 | 133 | 92 | 150 | 117 | 83 | 92 | 67 | 9 | |
| | Pharmaceuticals | Rx subsidy | ● | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Layman-adapted pharmaceuticals? | | ● | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |
| Access to new drugs (time to subsidy) | | ● | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |

- = Good
- = Intermediary
- = Poor
- n.a. = Data not available

Euro Health Consumer Index 2008

For more info please visit: www.healthpowerhouse.com

Euro Health Consumer Index at a glance:

Winner: Netherlands
Runner-up: Denmark
Third place: Austria

Subcategories:

Patient rights and information:
 Denmark

e-Health:
 Denmark

Waiting time for treatment:
 Germany, Luxembourg, Switzerland

Outcomes:
 Sweden

Range and reach of services provided:
 Netherlands


Pharmaceuticals:
 Austria

| SUBDISCIPLINE | INDICATOR | Austria | Belgium | Bulgaria | Croatia | Cyprus | Czech Republic | Denmark | Estonia | Finland | France | F.R. Macedonia | Germany | Greece | Hungary | Ireland | Italy | Latvia | Lithuania | Luxembourg | Malta | Netherlands | Norway | Poland | Portugal | Romania | |
|--------------------------------|---|---------|---------|----------|---------|--------|----------------|---------|---------|---------|--------|----------------|---------|--------|---------|---------|-------|--------|-----------|------------|-------|-------------|--------|--------|----------|---------|----|
| Patient rights and information | Healthcare law based on Patients' Rights | ● | ● | ○ | ● | ● | ○ | ● | ● | ● | ● | ● | ○ | ● | ● | ○ | ● | ○ | ● | ○ | ○ | ● | ● | ● | ● | ● | |
| | Patient organisations involved in decision making | ○ | ● | ○ | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ○ | ● | ● | ○ | ○ | ● | ○ | ○ | ○ | |
| | No-fault malpractice insurance | ○ | ○ | ○ | ○ | ○ | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| | Right to second opinion | ● | ● | ○ | ○ | ○ | ● | ● | ● | ○ | ● | ● | ● | ● | ● | ● | ○ | ○ | ○ | ● | ● | ○ | ○ | ○ | ○ | ○ | ○ |
| | Access to own medical record | ● | ○ | ● | ● | ○ | ● | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| | Register of legit doctors | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| | Web or 24/7 telephone HC info | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| | Cross-border care information | ○ | ● | ● | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | n.a. | ○ | ○ | ○ |
| | subdiscipline weighted score | | 100 | 106 | 88 | 94 | 88 | 81 | 144 | 125 | 131 | 113 | 88 | 100 | 100 | 119 | 88 | 100 | 56 | 131 | 106 | 94 | 125 | 106 | 94 | 63 | 81 |
| e-Health | Provider catalogue with quality ranking | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |
| | EHI penetration | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |
| | e-transfer of medical data | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |
| | e-prescriptions | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |
| | Subdiscipline weighted score | | 50 | 42 | 50 | 33 | 50 | 42 | 100 | 50 | 58 | 50 | 50 | 50 | 33 | 58 | 42 | 42 | 33 | 33 | 42 | 33 | 92 | 75 | 33 | 42 | 33 |
| Outcomes | Family doctor same day access | ● | ● | ● | ● | ○ | ● | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |
| | Subdiscipline weighted score | ● | ● | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |
| | Heart infarct case fatality | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| | Infant deaths | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| | Cancer 5-year survival | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| | Avoidable deaths – years of Life Lost | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |
| | MRSA infections | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |
| | Rate of decline of suicide | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |
| | % of patients with high HbA1c levels (> 7) | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |
| | Subdiscipline weighted score | | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Pharmaceuticals | Cataract operations | ○ | ○ | n.a. | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | n.a. | n.a. | ○ | ○ | ○ | ○ | ○ | n.a. | |
| | Minimal payments to doctors | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |
| | Subdiscipline weighted score | | 108 | 133 | 58 | 75 | 75 | 92 | 117 | 92 | 133 | 108 | 75 | 100 | 67 | 92 | 92 | 109 | 100 | 67 | 133 | 92 | 150 | 117 | 83 | 92 | 67 |
| | Rx subsidy | ● | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| | Layman-adapted pharmacopels? | ● | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Pharmaceuticals | New cancer drugs deployment speed | ● | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |
| | Access to new drugs (time to subsidy) | ● | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | n.a. | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |

Outcomes

● = Good
 ○ = Average
 n.a. = Data not available


Total scores in Euro Health Consumer Index 2008



| | |
|----------|---|
| Germany | Fantastic for access to healthcare, but surprisingly mediocre Outcomes and Range and Reach of services. Germany does not actively invite <i>e.g.</i> women to mammography screening, and has a poor coverage in spite of unlimited access. You want healthcare information – ask your doctor! |
| Slovenia | Really improving on Patients' Rights and Information. Decent outcomes, but Range and Reach of services and Waiting times have scope for improvement. Still poor access to new medicines. |

Nemski zdr. sistem

- Sistem obveznega zdr. zavarovanja (Bismarckov model)
- **JAVNI SISTEM ZDR. ZAVAROVANJA (Gesetzliche Krankenversicherung):** 166 zdr. zavarovalnic (Krankenkassen) -> 89% prebivalstva
- **PRIVATNI SISTEM ZDR. ZAVAROVANJA:** ca 11% v privatnih zdr. zavarovalnicah





■ JAVNI SISTEM ZDR. ZAVAROVANJA:

- Obvezno članstvo za zaposlene, ki imajo letni bruto dohodek manjši od € 48.150
- Premije niso odvisne od tveganja in so sorazmerne z dohodkom do nivoja € 3.600 na mesec (2008)
- Prispevna stopnja: 15.5% of bruto dohodka income (od 1.1.2011)
- Prispevki se porazdelijo med delojemalce in delodajalce

- Prosta izbira med različnimi zavarovalnicami
- Enaka premija
- Zakonski partner brez dohodka in otroci so vključeni brez doplacid






■ Doplacila bolnikov:


- 10 % (min 5 €, max 10 €) za zdravila na recept
- 10 € na kvartal za obisk pri zdravniku
- 10 € za bolnišnični dan
- PKV: placilo vnaprej, povrne zavarovalnica

■ Mocno decentraliziran sistem


% BDP za zdravstvo, 2008



Skupna poraba v zdravstvu: 245 milijard EUR



Ca 40
mil. EUR



Slika 15. Struktura realiziranih odhodkov ZZZS za zdravstvene dejavnosti v letu 2009.



- **Financiranje zdr. dejavnosti:**

- **Ambulantna oskrba:**

- storitveni sistem (določanje vrednosti točke na 3 mesece – regionalni nivo)

- **Bolnisnice:**


- SPP sistem

Ambulantna oskrba

- Pribl. 120.000 zdravnikov
- 49% splosnih zdravnikov
- Samozaposleni
- Prosta izbira zdravnika
- Pribl. 10 obiskov/leto (EU:6.8)

Bolnisnicna oskrba


- 2.087 bolnisnic
- 17,2 milionov bolnikov/leto
- Povprecno zdravljenje: 8,3 dni




CLOVESKI KAPITAL



- **10,6 %** vseh zaposlenih dela v zdravstvu (4,3 miliona)




St. medicinskih sester/1000 prebivalcev




Tezave...


- Starajoca se populacija



- 
- Narascajoci stroški zaradi novih, dragih zdr. tehnologij
 - Povečana pričakovanja ljudi
 - Zmanjšano zanimanje mladih za zdravstvene poklice



st. diplomiranih zdravnikov



LEKARNE

- Lastnistvo
- 19.5.2009 – Evropsko sodisce potrdilo legalnost prepovedi lastništva za nefarmacevte
- Max 4 lekarne v lasti ene osebe
- NI omejitev na odprtje lekarn



23.12.2010



23.12.2010




23.12.2010


- 21.548 lekarn =>
1 lekarna na
3.800 oseb

| | |
|----------------|--------------|
| Denmark | 16,800 |
| Sweden | 10,700 |
| Netherlands | 9,400 |
| Slovenia | 7,400 |
| Austria | 6,900 |
| Finland | 6,500 |
| Czech Republic | 5,500 |
| Luxembourg | 5,200 |
| Hungary | 5,000 |
| United Kingdom | 4,900 |
| Slovakia | 4,600 |
| Estonia | 4,300 |
| Germany | 3,800 |
| Portugal | 3,800 |
| Poland | 3,500 |
| Italy | 3,300 |
| Ireland | 3,000 |
| France | 2,700 |
| Latvia | 2,600 |
| Lithuania | 2,300 |
| Spain | 2,100 |
| Belgium | 2,000 |
| Malta | 1,900 |
| Cyprus | 1,700 |
| Greece | 1,200 |


Pharmacies opened



Pharmacies closed



■ 48 tisoč farmacevtov v zunanjih lekarnah






■ Ugled lekarn je precej visok:

- 87% Nemcev ima visoko stopnjo zaupanja v farmacevte
- 82% meni, da lekarne nudijo storitve visoke kakovosti
- 65% Nemcev obisce za nasvet pri manjsih tezavah najprej lekarno

■ Financiranje:


- zdravila na recept: 8,10 EUR na izdano zdravilo (skatlico) + 3 % na veleprodajno ceno
- OTC: proste marže

Measured in sales value:



- 1) Supplementary assortment
- 2) Patient care products
- 3) Unrestricted OTC pharmaceuticals*

Measured per units:



- 1) Unrestricted OTC pharmaceuticals*

* Pharmaceuticals which may be sold outside pharmacies (e.o. by chemists)

- Internetne lekarne
 - E-marketing (e-casopis)
- Narocanje zdravil po postu



Bestellschein

einen ausgefüllten Bestellschein.



Bitte in **Großbuchstaben** ausfüllen!

9W351-002

Anschrift Frau Herr

Vorname _____ Nachname _____

Straße _____ Hausnummer _____

PLZ _____ Ort _____

Telefon tagsüber – auch Mobiltelefon (für Rückfragen) _____

Geburtsdatum _____

Lieferadresse
 Falls abweichend von Ihrer Anschrift. Bitte bei **jeder Bestellung** angeben.

Vorname _____ Nachname _____

Firma/Adresszusatz _____

Straße _____ Hausnummer _____

PLZ _____ Ort _____

Bankdaten

Ich zahle bequem per **Bankeinzug**. Ich zahle per **Rechnung** nach Erhalt meiner Medikamente.

Kontonummer _____ BLZ _____

Bank _____

Kontoinhaber _____
 Hiermit ermächtige ich DocMorris bis auf Widerruf, die von mir zu entrichtenden Zahlungen bei Fälligkeit zulasten meines Kontos per Lastschrift einzuziehen.

Datum _____ Unterschrift _____

- bei Bestellungen mit Rezept
- für Erstbesteller
- **Neu: ab 20,- Euro Bestellwert bei rezeptfreien Medikamenten**

Versandkosten

0,- Euro

Kooperationspartner: _____ **Mitglieds-Nr./Kennwort:** _____

Rezeptpflichtige Medikamente

Ich lege **Kassenrezept(e) und/oder** **Privatrezept(e)** bei.
 (Bitte diese Medikamente nicht gesondert unten in die Bestellzeilen eintragen.)

Falls Sie von der Zuzahlung befreit sind, legen Sie bitte einmal jährlich eine Kopie Ihres Befreiungsnachweises bei.

Ja, **bitte schicken Sie mir kostenlos mein persönliches Medikationsprofil.**

Haben Sie Fragen zu Ihrer Medikation?

Zu Wechselwirkungen, zur Dosierung oder zu unerwünschten Wirkungen? Rufen Sie uns an, wir beraten Sie gerne:


0180 5 - 48 44 44 (14 ct/min*)


Rezeptfreie Medikamente (Bitte hier keine Medikamente von Ihrem Rezept eintragen.)

| PZN (Bestellnummer)** | Medikament/Artikel | Form (z.B. Tabl., Salbe) | Packungsgröße (z.B. 100 g, 50 Tabl.) | Anzahl/Packungen |
|-----------------------|--------------------|--------------------------|--------------------------------------|------------------|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

* max. 42 ct/min aus dem dt. Mobilfunknetz. Verantwortlich: DocMorris N.V., Heerlen, Niederlande, KVK-Nr. 14066093.

Politika na področju zdravil





- Ceno zdravila doloci proizvajalec
- Vendar, na določitev cene vplivajo:
 - Možna postavitev referencne cene (zavarovalnica plača le referencno ceno)
 - Možna postavitev maksimalne cene na podlagi neugodne stroškovne učinkovitosti
 - Pogajanja za popuste (predvsem generična zdravila)
- Dolocena zdravila izvzeta iz financiranja:
 - „lifestyle“ zdravila
 - OTC
 - Zdravila z nedokazano tepijsko koristjo (neg. lista)

Popusti na ceno

- Obvezni popusti:
 - 16% za nereferečna zdravila
 - 10% za generike
- Prostovoljni popusti
 - Lyfecycle management: npr. Betaferon
 - Nadaljevanje reimbursiranja: npr. Lantus in Levemir
 - Znižanje razlike do referencne cene: npr. Sortis
 - Risk-sharing: npr. Aclasta (zolendronska k.)
 - Dogovori o celokupnem proračunu za določeno zdravilo: npr. Lucentis (ranibizumab)
- Vecina dogovor je se vedno za generike (96% po številu); top 5: simvastatin, metamizole, levothyroxine, ibuprofen, metoprolol (ca 820 mio EUR prihrankov)

Every € 100 spent by SHI on pharmaceuticals is allocated as follows:

| | 2007 | 2008 | 2009 |
|-----------------|-------|-------|-------|
| Industry | 64.00 | 64.50 | 65.20 |
| Exchequer (VAT) | 16.00 | 16.00 | 16.00 |
| Pharmacies | 15.90 | 15.50 | 14.90 |
| Wholesalers | 4.10 | 4.00 | 3.90 |


Institucije

- BMG (Bundesministerium für Gesundheit) [Slide 37](#)
- BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)
 - registracija zdravil (~JAZMP)
- G-BA (Gemeinsamer Bundesausschuss)
 - doloca referencne skupine
 - izdaja smernice predpisovanja (obvezne)
 - naroca vrednotenje koristi zdravil in naknadno odloca o reimbursiranju
 - predstavniki zdravnikov, bolnisnic in zdr. zavarovalnic
- G-KV (Gemeinsamer Krankenkassen Spitzenverband)
 - Zastopa interese zavarovalnic
 - Doloci referencne cene
 - Pogajanje s proizvajalci
- IQWiG (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen)
 - Neodvisno znanstveno telo (2004)
 - vrednoti dodane koristi in strokovno ucinkovitost zdravil



Dr. Philipp Rösler


23.12.2010

- 
- G-BA lahko zaprosi IQWiG za formalno oceno dodane vrednosti oz. stroškovne učinkovitosti

 - Na podlagi te, G-BA lahko:
 - Doloci pogoje, pod katerimi je zdravilo reimbursirano
 - Izloci doloceno zdravilo iz rembursiranja
 - Doloci maksimalno ceno, npr. Analogi insulina
 - Ustvari novo referencno skupino

IQWiG


- IQWiG (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen)
- Na zahtevo G-BA ovrednotijo določeno terapijsko področje
- Objavljena in transparentna metodologija (2009)
- Uporablja pristop krivulje nedominiranih strategij



Referencne cene (Festbetrag)

- 3-nivojski referencni sistem
 - Nivo 1: identicne akt. Uc., nacin aplikacije, biorazpolozljivost (velja za genericna zdravila)
 - Nivo 2: Terapijsko oz. farmakolosko primerljive akt. Uc. (lahko vkljucuje tudi patentirana zdravila)
 - Nivo 3: Zdravila s primerljivim terapijskim ucinkom (kombinacije)
- Pravila:
 - V novi referencne potrebna vsaj 3 zdravila
 - Dolocitev referencne cene je zapletena (ni enostavne formule)
 - Referencne cene se dolocajo periodicno
 - Reimbursira se referencna cena, potencialno razliko placa bolnik

Razlika placa pacient



Krankenkassen

- Svojim članom morajo nuditi določeno minimalno raven zdr. oskrbe, ki jo krijejo, lahko pa nudijo dodatne ugodnosti
- Največje delujejo na nacionalnem nivoju, regionalne
- Izbira zavarovalnice običajno vezana na delodajalca
- KK se pogaja s farm. ind. in veletrgovci za ceno zdravil, se posebej generikov
- Narekujejo lekarnam, katera zdravila morajo izdati njihovim članom
- Sodelujejo z regionalnim zdravniškim združenjem za zagotovitev racionalnega predpisovanja zdravil

Kassenärztliche Vereinigungen

- Znotraj ene dezele obstaja eno zdravniško združenje
- Zavarovalnice in KV določijo letni proračun, KV odgovorna za upravljanje
- KV placuje zdravnikom na podlagi storitvenega sistema
- KV nadzoruje zdravnike glede njihovega predpisovanja zdravil in sledenja smernicam;
- Dolocajo tarčne vrednosti (indeksi kakovosti) predpisovanja



23.12.2010


AMNOG

- Arzneimittelneuordnungsgesetz
- S 1.1.2011
- Namen:
 - Znižati cene zdravil
- Nacin:
 - Povišanje obveznega popusta za nereferenčna zdravila iz 6% na 16% (velja od 1.8.2010)
 - Zamrznitev cen zdravil do 2013 (velja od 1.8.2010)
 - Dolocitev koristi za vsa nova zdravila in pogajanja za obvezen popust
- Pricakovani prihranki:
 - 3,5 milijarde EUR letno



Faire Preise für Arzneimittel

Preisgestaltung in der GKV nach dem Arzneimittelmarktneuordnungsgesetz (AMNOG)



- Breme dokaza dodane koristi na strani proizvajalca
- Popusti postajajo obvezni
- Dodana korist:
 - Pricakovani popusti ca 30%
 - Velja za vse KK
 - Mozni dodatni popusti oz. dogovori za posamezne KK
- Brez dodane vrednosti:
 - referencna cena
- Genericna zdravila – farmacevt bo lahko izdal tudi genericno zdravilo, ki ni v dogovoru z KK, ce bo bolnik placal razliko (vecja izbira na strani pacienta)


Bolnisnicna zdravila

- Vključena v SPP sistem
- Odbor za zdravila določa,
 - katera zdravila so vključena na seznam
 - kdo predpisuje določena zdravila
- Bolnisnice se pogajajo za cene
- Združevanje v skupine za boljše pogajalsko izhodišče





POVZETEK

- 
- Financiranje: Zdravstveno zavarovanje
 - Decentraliziran sistem
 - Zdravstvena oskrba
 - Zdravila:
 - Prosta določitev cene
 - Pogajanja za rabate
 - Referencne cene
 - Smernice predpisovanja
 - AMNOG



HVALA ZA POZORNOST!